New drug cocktail aims to fight tough stomach cancer
NCT ID NCT07584135
First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This Phase 3 trial tests a new drug called JS107 combined with toripalimab and chemotherapy against a standard treatment for advanced stomach cancer that has a specific marker (CLDN18.2). The study plans to enroll 600 people whose cancer has spread and cannot be removed by surgery. The goal is to see if the new combination helps patients live longer without their cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JS107 (a drug) combined with toripalimab and chemotherapy (oxaliplatin and capecitabine)
What this could lead to
If successful, this could offer a new first-line treatment option for people with a specific type of advanced stomach cancer, potentially improving how long they live without the cancer growing.
What could go wrong
This is an early-stage Phase 3 trial that hasn't started recruiting yet. The new combination may not be more effective than the existing treatment and could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••